A NOVEL PPAR-GAMMA AGONIST, AS002, INDUCES PPAR-GAMMA-ACTIVITY IN ULCERATIVE COLITIS MUCOSA, AND PREVENTS AND REVERSES INFLAMMATION IN DSS COLITIS.

(1) Department of Clinical and Experimental Medicine,Faculty of Health Sciences Linköping University,Linköping,Sweden

(2) Translational Cancer Research,Cancer Center at Medicon Village,Lund,Sweden

(3) Albireo Pharma AB,Gothenburg,Sweden



This item was part of UEG Week 2015

This item can be cited as: United European Gastroenterology Journal; 2015: 2 (Supplement 1)